Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer
- Conditions
- Merkel Cell CarcinomaSmall Cell Lung Cancer
- Interventions
- Biological: XmAb18087
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2023-04-20
- Lead Sponsor
- Xencor, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT04590781
- Locations
- 🇺🇸
OU Health, Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
🇺🇸Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
🇺🇸Memorial Sloan Kettering, New York, New York, United States
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
- Conditions
- Triple Negative Breast CancerHepatocellular CarcinomaEpithelial Ovarian CancerFallopian Tube CancerNon-small Cell Lung CarcinomaAdvanced or Metastatic Solid TumorsSquamous Cell Anal CancerSmall Cell Lung CarcinomaGastric or Gastroesophageal Junction AdenocarcinomaSquamous Cell Vulvar Carcinoma
- Interventions
- Biological: XmAb®22841Biological: Pembrolizumab (Keytruda®)
- First Posted Date
- 2019-02-21
- Last Posted Date
- 2023-03-30
- Lead Sponsor
- Xencor, Inc.
- Target Recruit Count
- 78
- Registration Number
- NCT03849469
- Locations
- 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
- Conditions
- Hepatocellular CarcinomaUrothelial CarcinomaColorectal CarcinomaPancreatic CarcinomaBreast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 NegativeMelanoma (Excluding Uveal Melanoma)Cervical CarcinomaNasopharyngeal CarcinomaRenal Cell CarcinomaNon-small Cell Lung Carcinoma
- Interventions
- Biological: XmAb®23104Biological: Yervoy® (ipilimumab)
- First Posted Date
- 2018-11-26
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Xencor, Inc.
- Target Recruit Count
- 198
- Registration Number
- NCT03752398
- Locations
- 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
- Conditions
- Squamous Cell Carcinoma of the PenisUrothelial CarcinomaNeuroendocrine CarcinomaCervical CancerThymomaThymic CarcinomaVulvar CarcinomaSolid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed TherapyRenal Cell CarcinomaGastric or Gastroesophageal Junction Adenocarcinoma
- Interventions
- Biological: XmAb20717
- First Posted Date
- 2018-05-07
- Last Posted Date
- 2022-12-01
- Lead Sponsor
- Xencor, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT03517488
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
🇺🇸UCLA Hematology-Oncology Clinic (Westwood), Los Angeles, California, United States
🇺🇸University of California San Diego Moores Cancer Center, San Diego, California, United States
Study Evaluating AMG 424 in Subjects With Multiple Myeloma
- First Posted Date
- 2018-02-26
- Last Posted Date
- 2023-03-07
- Lead Sponsor
- Xencor, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT03445663
- Locations
- 🇦🇺
Research Site, Fitzroy, Victoria, Australia
A Study of XmAb®18087 in Subjects With NET and GIST
- Conditions
- Gastrointestinal NeoplasmNeuroendocrine Tumor
- Interventions
- Biological: XmAb18087
- First Posted Date
- 2018-01-26
- Last Posted Date
- 2022-05-10
- Lead Sponsor
- Xencor, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT03411915
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸City of Hope Medical Center, Duarte, California, United States
🇺🇸Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies
- Conditions
- B-cell Non-Hodgkins LymphomaChronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Xencor, Inc.
- Target Recruit Count
- 154
- Registration Number
- NCT02924402
- Locations
- 🇺🇸
The University of Chicago Medicine, Chicago, Illinois, United States
🇺🇸Northside Hospital, Atlanta, Georgia, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7195
- First Posted Date
- 2016-08-29
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Xencor, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT02881853
- Locations
- 🇺🇸
ICON Early Phase Services, LLC, San Antonio, Texas, United States
XmAb5871 Bioavailability Study
- First Posted Date
- 2016-08-15
- Last Posted Date
- 2017-12-08
- Lead Sponsor
- Xencor, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT02867098
- Locations
- 🇺🇸
PAREXEL, Early Phase Clinical Unit-Los Angeles, Glendale, California, United States
PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies
- Conditions
- Blastic Plasmacytoid Dendritic Cell NeoplasmChronic Myeloid Leukemia, Blast CrisisB-cell Acute Lymphoblastic LeukemiaAcute Myelogenous Leukemia
- Interventions
- Biological: XmAb14045
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2022-03-08
- Lead Sponsor
- Xencor, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT02730312
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
🇺🇸Mayo Clinic Jacksonville, Jacksonville, Florida, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States